Tellgen (SHE:300642) obtained regulatory approval for the expanded use of its human papillomavirus nucleic acid detection and 16/18 genotyping kit, according to a filing with the Shenzhen bourse.
China's National Medical Products Administration approved the kit's use for primary cervical cancer screening, co-testing with cervical cytology for screening, and triaging patients with ambiguous ASC-US cytology results.
Shares of the detection products company closed 2% lower Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.